Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 6/2011

01.12.2011 | Review Article

Medical Management of Chronic Liver Diseases in Children (Part I)

Focus on Curable or Potentially Curable Diseases

verfasst von: Professor Mortada H. F. El-Shabrawi, Naglaa M. Kamal

Erschienen in: Pediatric Drugs | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

The management of children with chronic liver disease (CLD) mandates a multidisciplinary approach. CLDs can be classified into ‘potentially’ curable, treatable non-curable, and end-stage diseases. Goals pertaining to the management of CLDs can be divided into prevention or minimization of progressive liver damage in curable CLD by treating the primary cause; prevention or control of complications in treatable CLD; and prediction of the outcome in end-stage CLD in order to deliver definitive therapy by surgical procedures, including liver transplantation.
Curative, specific therapies aimed at the primary causes of CLDs are, if possible, best considered by a pediatric hepatologist. Medical management of CLDs in children will be reviewed in two parts, with part I (this article) specifically focusing on ‘potentially’ curable CLDs.
Dietary modification is the cornerstone of management for galactosemia, hereditary fructose intolerance, and certain glycogen storage diseases, as well as non-alcoholic steatohepatitis. It is also essential in tyrosinemia, in addition to nitisinone [2-(nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione] therapy, as well as in Wilson disease along with copper-chelating agents such as D-penicillamine, triethylenetetramine dihydrochloride, and ammonium tetrathiomolybdate. Zinc and antioxidants are adjuvant drugs in Wilson disease. New advances in chronic viral hepatitis have been made with the advent of oral antivirals. In children, currently available drugs for the treatment of chronic hepatitis B virus infection are standard interferon (IFN)-α-2, pegylated IFN-α-2 (PG-IFN), and lamivudine. In adults, adefovir and entecavir have also been licensed, whereas telbivudine, emtricitabine, tenofovir disoproxil fumarate, clevudine, and thymosin α-1 are currently undergoing clinical testing. For chronic hepatitis C virus infection, the most accepted treatment is PG-IFN plus ribavirin. Corticosteroids, with or without azathioprine, remain the basic strategy for inducing remission in autoimmune hepatitis. Ciclosporin (cyclosporine) and other immune suppressants may be used for patients who do not achieve remission, or who have significant side effects, with corticosteroid/azathioprine therapy.
The above therapies can prevent, or at least minimize, progression of liver damage, particularly if started early, leading to an almost normal quality of life in affected children.
Literatur
1.
El-Shabrawi MHF, Kamal NM. Medical management of chronic liver diseases (CLD) in children (part II): focus on the complications of CLD, and CLD that require special considerations. Pediatr Drugs 2011; 13(6): 371–83
2.
Elsas LJ. Galactosemia. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993–2000 Feb 4 [updated 2010 Oct 26]
3.
Elsas LJ. Prenatal diagnosis of galactose-1-phosphate uridyltransferase (GALT)-deficient galactosemia. Prenat Diagn 2001; 21: 302–3PubMed
4.
Zlatunich CO, Packman S. Galactosaemia: early treatment with an elemental formula. J Inherit Metab Dis 2005; 28: 163–8PubMed
5.
Berry GT, Moate PJ, Reynolds RA, et al. The rate of de novo galactose synthesis in patients with galactose-1-phosphate uridyltransferase deficiency. Mol Genet Metab 2004; 81: 22–30PubMed
6.
Bosch AM, Bakker HD, Wenniger-Prick LJ, et al. High tolerance for oral galactose in classical galactosaemia: dietary implications. Arch Dis Child 2004; 89: 1034–6PubMed
7.
Schadewaldt P, Kamalanathan L, Hammen HW, et al. Age dependence of endogenous galactose formation in Q188R homozygous galactosemic patients. Mol Genet Metab 2004; 81: 31–44PubMed
8.
Elsas L, Acosta P. Nutritional support of inherited metabolic disease. In: Shils M, Olson J, Shike M, et al., editors. Modern nutrition in health and disease. 9th ed. Baltimore (MD): Williams & Wilkins, 1998: 1003–56
9.
Elsas LJ, Acosta PB. Inherited metabolic disease: aminoacids, organic acids and galactose. In: Shils ME, Shike M, Ross AC, et al., editors. Modern nutrition in health and disease. 10th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2006: 909–59
10.
Hardy S, Kleinman RE. Cirrhosis and chronic liver failure. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007: 97–137
11.
Panis B, Vermeer C, van Kroonenburgh MJ, et al. Effect of calcium, vitamins K1 and D3 on bone in galactosemia. Bone 2006; 39: 1123–9PubMed
12.
Menezo YJ, Lescaille M, Nicollet B, et al. Pregnancy and delivery after stimulation with rFSH of a galatosemia patient suffering hypergonadotropic hypogonadism: case report. J Assist Reprod Genet 2004; 21: 89–90PubMed
13.
Rubio-Gozalbo M, Gubbels C, Bakker J, et al. Gonadal function in male and female patients with classic galactosemia. Hum Reprod Update 2010; 16: 177–88PubMed
14.
Tang M, Wierenga K, Elsas LJ, et al. Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors. Chem Biol Interact 2010 Dec 5; 188(3): 376–85PubMed
15.
Ghishan FK, Zawaideh M. Inborn errors of carbohydrate metabolism. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007: 595–625
16.
Nordlie RC. Fine tuning of blood glucose concentrations. Trends Biochem Sci 1985; 10: 70–5
17.
Chen YT. Glycogen storage diseases. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001: 1521–51
18.
Chen YT. Glycogen storage disease and other inherited disorders of carbohydrate metabolism. In: Kasper DL, Braunwald E, Fauci A, et al., editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill, 2004
19.
Chen YT, Bali DS. Glycogen storage diseases. In: Fuchs J, Podda M, editors. Encyclopedia of diagnostic genomics and proteomics. New York: Marcel Dekker Inc, 2004: 543–9
20.
Matern D, Seydewitz HH, Bali D, et al. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr 2002; 161Suppl. 1: S10–9PubMed
21.
Hiraiwa H, Pan CJ, Lin B, et al. Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b. J Biol Chem 1999; 274: 5532–6PubMed
22.
Rake JP, Visser G, Labrune P, et al. Guidelines for management of glycogen storage disease type I: European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161: 112–9
23.
Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161Suppl. 1: S20–34PubMed
24.
Veiga-da-Cunha M, Gerin I, Chen YT, et al. A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glyco-gen-storage disease types Ib and Ic. Am J Hum Genet 1998; 63: 976–83PubMed
25.
Ekstein J, Rubin BY, Anderson SL, et al. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet A 2004; 129A: 162–4PubMed
26.
Chou JY, Matern D, Mansfield BC, et al. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med 2002; 2: 121–43PubMed
27.
Bali DS, Chen YT, Goldstein JL. Glycogen storage disease type I. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993–2006 Apr 19 [updated 2010 Dec 23]
28.
Schwenk WF, Haymond MW. Optimal rate of enteral glucose administration in children with glycogen storage disease type I. N Engl J Med 1986; 314: 682–5PubMed
29.
Ghishan FK, Greene HL. Inborn errors of metabolism that cause permanent injury to the liver. In: Zakim D, Boyer T, editors. Hepatology: a textbook of liver disease. 2nd ed. Philadelphia (PA): WB Saunders, 1990; 49: 1300–48
30.
Chen Y-T, Cornblath M, Sidbury JB. Cornstarch therapy in type I glycogen storage disease. N Engl J Med 1984; 310: 171–5PubMed
31.
Wolfsdorf JI, Crigler JF. Effect of continuous glucose therapy began in infancy on the long-term clinical course of patients with type I glycogen storage disease. J Pediatr Gastroenterol Nutr 1999; 29: 136–43PubMed
32.
Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr 2002; 161Suppl. 1: S35–9PubMed
33.
Weinstein DA, Somers MJ, Wolfsdorf JI. Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr 2001; 138: 378–82PubMed
34.
Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev Endocr Metab Disord 2003; 4: 95–102PubMed
35.
Myrup B, Valerius NH, Mortensen PB. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor. Gut 1998; 42: 127–30PubMed
36.
Visser G, Rake JP, Fernandes J, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr 2000; 137: 187–91PubMed
37.
Calderwood S, Kilpatrick L, Douglas SD, et al. Recombinant human gran-ulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood 2001; 97: 376–82PubMed
38.
Steinmetz BA, Martin MG, Roberts RL. Granulocyte-macrophage colony-stimulating factor for treating gastrostomy tube site healing in a child with glycogen storage disease type Ib. J Pediatr Gastroenterol Nutr 2001; 33: 94–6PubMed
39.
Visser G, Rake JP, Labrune P, et al. Consensus guidelines for management of glycogen storage disease type 1b-European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 2002; 161: 120–3
40.
Bhattacharya K, Orton RC, Qi X, et al. A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis 2007; 30: 350–7PubMed
41.
Yiu WH, Pan CJ, Allamarvdasht M, et al. Glucose-6-phosphate transporter gene therapy corrects metabolic and myeloid abnormalities in glycogen storage disease type Ib mice. Gene Ther 2007; 14: 219–26PubMed
42.
Dagli AI, Weinstein DA. Glycogen storage disease type VI. In: Pagon RA, Bird TC, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993–2009 Apr 23 [updated 2011 May 17]
43.
Bell L, Sherwood WG. Current practices and improved recommendations for treating hereditary fructose intolerance. J Am Diet Assoc 1987; 87: 721–30PubMed
44.
Fox IH, Kelley WN. Studies on the mechanism of fructose induced hyperuricemia in man. Metabolism 1972; 21: 713–21PubMed
45.
Narins RG, Weisberg JS, Myers AR. Effects of carbohydrates on uric acid metabolism. Metabolism 1974; 23: 455–65PubMed
46.
Heuckenkamp P-U, Zollner N. Fructose-induced hyperuricaemia. Lancet 1971; II: 808–9
47.
Sahebjami H, Scalettar R. Effects of fructose infusion on lactate and uric acid metabolism. Lancet 1971; I: 366–9
48.
Levin B, Snodgrass GJ, Oberholzer VG, et al. Fructosaemia: observations on seven cases. Am J Med 1968; 45: 826–38PubMed
49.
Cornblath M, Rosenthal IM, Reisner SH, et al. Hereditary fructose intolerance. N Engl J Med 1963; 269: 1271–8PubMed
50.
Froesch ER, Wolf HP, Baitsch H, et al. Hereditary fructose intolerance: an inborn defect of hepatic fructose-1-phosphate splitting aldolase. Am J Med 1963; 34: 151–67PubMed
51.
Perheentupa J, Raivio KO, Nikkila EA. Hereditary fructose intolerance. Acta Med Scand 1972; 542 Suppl.: 65–75
52.
Bouteldja N, Timson DJ. The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis 2010 Apr; 33(2): 105–12PubMed
53.
Anderson TA. Recent trends in carbohydrate consumption. Annu Rev Nutr 1982; 2: 113–32PubMed
54.
Gitzelmann R, Steinmann B, Van den Berghe G. Disorders of fructose metabolism. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, editors. The metabolic basis of inherited disease. 6th ed. New York: McGraw-Hill, 1989: 399–424
55.
Oberhaensli RD, Rajagopalan B, Taylor DJ, et al. Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy. Lancet 1987; II: 931–7
56.
Mock DM, Perman JA, Thaler MM, et al. Chronic fructose intoxication after infancy in children with hereditary fructose intolerance: a cause of growth retardation. N Engl J Med 1983; 309: 764–70PubMed
57.
Shallenberger RS. Occurrence of various sugars in foods. In: Sipple HL, McNutt KW, editors. Sugars in nutrition. New York: Academic Press, 1974: 67–80
58.
Hardinge MG, Swarner JB, Crooks H. Carbohydrates in foods. J Am Diet Assoc 1965; 46: 197–204PubMed
59.
Somogyi JC, Trautner K. Der Glukose-, Fructose- und Saccharosegehalt verschiedener Gemusearten. Schweiz MedWochenschr 1974; 104: 177–82
60.
Wyke RJ, Rajkovic IA, Eddleston AL, et al. Defective opsonization and complement deficiency in serum from patients with fulminant hepatic failure. Gut 1980; 21: 643–9PubMed
61.
Odievre M, Gentil C, Gautier M, et al. Hereditary fructose intolerance in childhood. Am J Dis Child 1978; 132: 605–8PubMed
62.
Carey RG, Balistreri WF. Metabolic diseases of the liver. In: Kliegman RM, Behrman RE, Jenson HB, et al., editors. Nelson textbook of pediatrics. 18th ed. Philadelphia (PA): Saunders Elsevier, 2008: 1675–80
63.
Cox DW, Roberts E. Wilson Disease. In: Pagon RA, Bird TC, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993–1999 Oct 22 [updated 2006 Jan 24]
64.
Farber M, Knuppel RA, Binkiewicz A, et al. Pregnancy and von Gierke’s disease. Obstet Gynecol 1976; 47: 226–8PubMed
65.
Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, et al. Does a vegetarian diet control Wilson’s disease? J Am Coll Nutr 1993 Oct; 12(5): 527–30PubMed
66.
Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003; 37: 1475–92PubMed
67.
Koeberl DD, Pinto C, Sun B, et al. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther 2008; 16: 665–72PubMed
68.
O’Connor JA, Sokol RJ. Copper metabolism and copper storage disease. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007: 626–60
69.
Schilsky ML, Scheinberg IH, Sternlieb I. Liver transplantation for Wilson’s disease: indications and outcome. Hepatology 1994; 19: 583–7PubMed
70.
Emre S, Atillasoy EO, Ozdemir S, et al. Orthotopic liver transplantation for Wilson’s disease: a single-center experience. Transplantation 2001; 72: 1232–6PubMed
71.
Sutcliffe RP, Maguire DD, Muiesan P, et al. Liver transplantation for Wilson’s disease: long-term results and quality-of-life assessment. Transplantation 2003; 75: 1003–6PubMed
72.
Merja A, Sari P, Matti KS, et al. Current strategies for the treatment of hereditary tyrosinemia type I. Pediatr Drugs 2006; 8(1): 47–54
73.
Sniderman King L, Trahms C, Scott CR. Tyrosinemia type 1. In: Pagon RA, Bird TC, Dolan CR, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle, 1993–2006 Jul 24 [updated 2008 Oct 21]
74.
Mitchell GA, Rezvani I. Tyrosine. In: Kliegman RM, Behrman RE, Jenson HB, et al., editors. Nelson textbook of pediatrics. 18th ed. Philadelphia (PA): Saunders Elsevier, 2008
75.
El-Karaksy H, Rashed M, El-Sayed R, et al. Clinical practice. NTBC therapy for tyrosinemia type 1: how much is enough? Eur J Pediatr 2010 Jun; 169(6): 689–93PubMed
76.
Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010 Jun; 11(6): 430–45PubMed
77.
Xanthakos SA, Balistreri WF. Liver disease associated with systemic disorders. In: Kliegman RM, Behrman RE, Jenson HB, et al., editors. Nelson textbook of pediatrics. 18th ed. Philadelphia (PA): Saunders Elsevier, 2008
78.
Federico A, Niosi M, Vecchio Blanco CD, et al. Emerging drugs for nonalcoholic fatty liver disease. Expert Opin Emerg Drugs 2008 Mar; 13(1): 145–58PubMed
79.
Portincasa P, Grattagliano I, Palmieri VO, et al. Current pharmacological treatment of nonalcoholic fatty liver. Curr Med Chem 2006; 13(24): 2889–900PubMed
80.
Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steato-hepatitis. Lancet 2001; 358(9285): 893–4PubMed
81.
Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of nonalcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20(1): 23–8PubMed
82.
Angelico F, Burattin M, Alessandri C, et al. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007; (1): CD005166
83.
Socha P, Horvath A, Vajro P, et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009; 48(5): 587–96PubMed
84.
Trappoliere M, Tuccillo C, Federico A, et al. The treatment of NAFLD. Eur Rev Med Pharmacol Sci 2005 Sep–Oct; 9(5): 299–304PubMed
85.
Trappoliere M, Federico A, Tuccillo C, et al. Effects of a new pharmacological complex (silybin+vitamin-E+phospholipids) on some markers of the metabolic syndrome and of liver fibrosis in patients with hepatic steatosis. Preliminary study. Minerva Gastroenterol Dietol 2005 Jun; 51(2): 193–9PubMed
86.
Cuestas ML, Mathet VL, Oubiña JR, et al. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection. Pharm Res 2010 Jul; 27(7): 1184–202PubMed
87.
Doerig C, Antonino A, Pache I, et al. Management of chronic hepatitis B [in French]. Rev Med Suisse 2010 Jan 27; 6(233): 168–70, 172-3PubMed
88.
Balsano C, Alisi A. Viral hepatitis B: established and emerging therapies. Curr Med Chem 2008; 15(9): 930–9PubMed
89.
Shah U, Kelly D, Chang MH, et al. Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr 2009 Apr; 48(4): 399–404PubMed
90.
Chang MH. Natural history and clinical management of chronic hepatitis B virus infection in children. Hepatol Int 2008 May; 2Suppl. 1: 28–36PubMed
91.
Hochman JA, Balistreri WF. Acute and chronic viral hepatitis. In: Suchy FJ, Sokol RJ, Balistreri WF, editors. Liver disease in children. 3rd ed. New York: Cambridge University Press, 2007: 369–446
92.
Liaw Y-F, the ACT-HBV Asia Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int 2006; 26: 47–58
93.
Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472–89PubMed
94.
Lok AS, McMahon BJ. Chronic hepatitis B (AASLD practice guidelines). Hepatology 2001; 34: 1225–41PubMed
95.
Anand AC, Puri P. Treatment of chronic hepatitis B: will entecavir and telbivudine do the trick? Trop Gastroenterol 2008 Apr–Jun; 29(2): 71–5PubMed
96.
Yazigi N, Balistreri WF. Viral hepatitis. In: Kliegman RM, Behrman RE, Jenson HB, et al., editors. Nelson textbook of pediatrics. 18th ed. Philadelphia (PA): Saunders Elsevier, 2008
97.
Sokal E. Drug treatment of pediatric chronic hepatitis B. Paediatr Drugs 2002; 4(6): 361–9PubMed
98.
Susan KJ, Lesley SJ. Lamivudine: in children and adolescents with chronic hepatitis B virus infection. Pediatr Drugs 2002; 4(10): 687–94
99.
Keeffe EB, Dieterich DT, Pawlotsky JM, et al. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 2008 Mar; 6(3): 268–74PubMed
100.
Neely MN, Rakhmanina NY. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin Pharmacokinet 2011 Mar 1; 50(3): 143–89PubMed
101.
Lee C, Custer JW, Rau RE. Formulary: penicillamine. In: Custer JW, Rau RE, editors. The Harriet Lane handbook, 18th ed. Philadelphia (PA): Mosby Elsevier, 2008: 938–9
102.
Vcev A. Management of side effects during antiviral therapy. Acta Med Croatica 2009 Dec; 63(5): 463–7PubMed
103.
Fontana RJ, Keeffe EB, Carey W, et al., for the National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002 May; 8(5): 433–9PubMed
104.
Adusumilli S. Tenofovir disoproxil fumarate for the treatment of hepatitis B infection. Drugs Today (Barc) 2009 Sep; 45(9): 679–85
105.
Duong A, Mousa SA. Current status of nucleoside antivirals in chronic hepatitis B. Drugs Today (Barc) 2009 Oct; 45(10): 751–61
106.
Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008 Jun; 47(6): 1863–71PubMed
107.
Sokal EM, Kelly D, Wirth S, et al. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol 2008 Apr; 48(4): 512–7PubMed
108.
Mubareka S, Leung V, Aoki FY, et al. Famciclovir: a focus on efficacy and safety. Expert Opin Drug Saf 2010 Jul; 9(4): 643–58PubMed
109.
Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem 2006; 13(23): 2839–55PubMed
110.
Mao HY, Shi TD. Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positivie chronic hepatitis B: a meta analysis [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2011 Jan; 19(1): 29–33PubMed
111.
Galoppo M, Galoppo C. Management of hepatitis C virus infection in childhood. Ann Hepatol 2010; 9 Suppl.: 98–102PubMed
112.
Davison SM, Kelly DA. Management strategies for hepatitis C virus infection in children. Paediatr Drugs 2008; 10(6): 357–65PubMed
113.
Lee C, Custer JW, Rau RE. Formulary: ribavirin. In: Custer JW, Rau RE, editors. The Harriet Lane handbook. 18th ed. Philadelphia (PA): Mosby Elsevier, 2008: 975–6
114.
Garg G, Kar P. Management of HCV infection: current issues and future options. Trop Gastroenterol 2009 Jan–Mar; 30(1): 11–8PubMed
115.
Cross TJ, Antoniades CG, Harrison PM. Current and future management of chronic hepatitis C infection. Postgrad Med J 2008 Apr; 84(990): 172–6PubMed
116.
Rai R, Deval J. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res 2011 May; 90(2): 93–101PubMed
117.
Lee C, Custer JW, Rau RE. Formulary: azathioprine. In: Custer JW, Rau RE, editors. The Harriet Lane Handbook. 18th ed. Philadelphia (PA): Mosby Elsevier, 2008: 742–3
118.
Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis 2009 Aug; 29(3): 273–85PubMed
119.
Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994 Dec; 21(6): 1040–7PubMed
120.
El-Shabrawi M, Wilkinson ML, Portmann B, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987 May; 92 (5 Pt 1): 1226–35PubMed
Metadaten
Titel
Medical Management of Chronic Liver Diseases in Children (Part I)
Focus on Curable or Potentially Curable Diseases
verfasst von
Professor Mortada H. F. El-Shabrawi
Naglaa M. Kamal
Publikationsdatum
01.12.2011
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 6/2011
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/11591610-000000000-00000

Weitere Artikel der Ausgabe 6/2011

Pediatric Drugs 6/2011 Zur Ausgabe

Current Opinion

Pediatric Drug-Resistant Tuberculosis

Announcement

Acknowledgment

Review Article

Medical Management of Chronic Liver Diseases (CLD) in Children (Part II)

Review Article

Acute Bacterial Meningitis in Infants and Children

Adis Drug Profile

DTaP5-IPV-Hib Vaccine (Pediacel®)

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise